Retrospective analysis of risk factors for thrombotic events due to the use of combined oral contraceptives

1. Trenor С.С. 3rd, Chung R.J., Michelson А.D., Neufeld E.J., Gordon C.M., Laufer M.R., Emans S.J. Hormonal contraception and thrombotic risk: a multidisciplinary approach. Pediatrics. 2011; 127(2): 347-57.
2. Dhont М. History of hormonal contraception. Eur. J. Contracept. Reprod. Health Care. 2010; 15(Suppl. 2): 12-8.
3. Макацария А.Д., Саидова Р.А. Гормональная контрацепция и тромбофилические состояния. M.: Триада-Х; 2004. 240с. [Makatsariya A.D., ed. Thrombohemorrhagic complications in obstetric practice. A guide for physicians. M.: MIA; 2011. 1050s. (in Russian)]
4. Chen М., Culwell К. Contraception for women with medical problems. Glob. Libr. Women’s Med. 2015. https://doi.org/10.3843/GLOWM.10382.
5. Lidegaard O., Edström B., Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception. 2002; 65(3): 187-96.
6. Suchon P., Al Frouh F., Henneuse A., Ibrahim M., Brunet D., Barthet M.C. et al. Risk factors for venous thromboembolism in women under combined oral contraceptive. Thromb. Haemost. 2016; 115(1):135-142.
7. Hugon-Rodin J., Horellou M., Conard J., Gompel A., Plu-Bureau G. Combined hormonal contraceptives and first venous thrombosis in young french women: impact of thrombotic family history. J. Endocr. Soc. 2017; 1(6): 762-71. https://doi.org/10.1210/js.2017-00090.
8. Макарация А.Д., ред. Тромбогеморрагические осложнения в акушерско-гинекологической практике. Руководство для врачей. M.: МИА; 2011. 1050с. [Makatsariya A. D., ed. Thrombohemorrhagic complications in obstetric practice. A guide for physicians. M.: MIA; 2011. 1050s. (in Russian)]
9. Gourdy Р., Bachelot А., Catteau-Jonard S., Christin-Maître S., Conard J., Fredenrich A. et al. Hormonal contraception in women at risk of vascular and metabolic disorders: Guidelines of the French Society of Endocrinology. Ann. Endocrinol. (Paris). 2012; 73(5): 469-87.
10. Rott H. Birth control pills and thrombotic risks: differences of contraception methods with and without estrogen. Hamostaseologie. 2019; 39(1): 42-8. https://doi.org/10.1055/s-0039-1677806.
11. Tans G., Vlieg H.A., Thomassen M.C., Curvers J., Bertina R.M., Rosing J. et al. Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. Br. J. Haematol. 2003; 122(3): 465-70.
12. Хамани Н.М. Особенности ведения беременности и родов у женщины с гомозиготной мутацией протромбина (Pt Thr165Met) и рецидивирующей ТЭЛА в анамнезе на фоне приема гормональной контрацепции. Акушерство, гинекология и репродукция. 2018; 12(1): 99-104.[Hamani N.M. Features of pregnancy and delivery in women with homozygous mutation of the prothrombin (Pt Thr165Met) and a history of recurrent pulmonary embolism receiving hormonal contraception. Obstetrics, gynecology and reproduction. 2018; 12(1): 99-104.(in Russian)]
13. Макацария А.Д., Бицадзе В.О., Акиньшина С.В. Тромбозы и тромбоэмболии в акушерско-гинекологической клинике. M.: МИА; 2007. 1064с. [Makatsariya A.D., Bitsadze V. O., Akinshina S. V. Thrombosis and thromboembolism in obstetric and gynecological clinic. M.: MIA; 2007. 1064 c. (in Russian)]
14. Wiegratz I., Lee J.H., Kutschera E., Winkler U.H., Kuhl H. Effect of four oral contraceptives on hemostatic parameters. Contraception. 2004; 70(2):97-106.
15. Bergendal A., Persson I., Odeberg J., Sundström A., Holmström M., Schulman S. et al. Association of venous thromboembolism with hormonal contraception and thrombophilic genotypes. Obstet. Gynecol. 2014; 124(3): 600-9.
16. Макацария А.Д., Хизроева Д.Х., Бицадзе В.О., Акиньшина С.В. Беременность и гомозиготные и сочетанные формы тромофилии у пациенток с тромботическим и акушерским отягощённым анамнезом. Тромбоз, гемостаз и реология. 2016; Приложение 3: 269-70.[Makatsariya A.D., Khizroeva D. H., Bitsadze V. O., Akinshina S. V. Pregnancy and homozygous and combined forms of thrombophilia in patients with a complicated thrombotic and obstetric history. Thrombosis, hemostasis and rheology. 2016; Annex 3: 269-70.(in Russian)]
17. Grimes D.A., Stuart G.S., Levi E.E. Screening women for oral contraception: can family history identify inherited thrombophilias? Obstet. Gynecol. 2012; 120(4): 889-95.
18. Jick H., Jick S.S., Gurewich V., Myers M.W., Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet. 1995; 346(8990): 1589-93.
19. Vlieg H.A., Helmerhorst F.M., Vandenbroucke J.P., Doggen C.J.M., Rosendaal F.R. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ. 2009; 339: b2921, 10.1136/bmj.b2921.
20. Lidegaard Ø., Nielsen L.H., Skovlund C.W., Skjeldestad F.E., Løkkegaard E. (2011) Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study 2001-9. BMJ. 2011; 343: d6423.
21. Dinger J., Assmann A., Mohner S. Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study. J. Fam. Plann. Reprod. Health Care. 2010; 36(3): 123-9.

Received 08.04.2019

Accepted 19.04.2019